## Review setup
- **Input scope** Full manuscript text, including abstract, introduction, methods, results, discussion, conclusion, and references as provided.
- **Assessment boundary** Scientific content, methodological rigor, validity of claims, and presentation quality. Editorial and stylistic issues are noted only where they affect scientific clarity.
- **Shared manuscript claim summary** The authors use in silico methods to identify GATA6 single nucleotide polymorphisms (SNPs) potentially associated with ventricular septal defect (VSD). They report that among 87 VSD-associated genes, GATA6 is a central hub in a 16-protein interaction network. From 680 missense SNPs, they prioritize four (rs387906813, rs387906817, rs387906818, rs387906820) and, after molecular dynamics simulations, conclude that rs387906818 (R456C) and rs387906820 (A467T) have the highest pathogenic potential for VSD.
- **Visible evidence base** All figures and tables are referenced in the text but not provided in the supplied material. Methods are described in detail. Results are presented as summary statements without raw data or quantitative outputs from the prediction tools.
- **Missing materials affecting confidence** Figures 1-12, Tables 1-6, and all tool-specific output files (e.g., SIFT, PolyPhen-2, MutPred2, STRING, AlphaFold3, GROMACS trajectories) are not available. This prevents independent verification of the reported scores, network parameters, and simulation analyses.

## Reviewer
- **Overall assessment** This manuscript presents a straightforward in silico pipeline for prioritizing GATA6 missense variants in VSD. The workflow is conventional and the tools are appropriate. However, the study is largely descriptive and confirmatory, with no experimental validation. The central claims regarding the pathogenic potential of rs387906818 and rs387906820 rest on computational predictions that are not benchmarked against known functional data. The absence of key quantitative results and figures in the supplied material limits the ability to assess technical soundness. The manuscript would benefit from clearer presentation of the filtering criteria, a more critical interpretation of the prediction scores, and a discussion of the limitations of in silico pathogenicity assessment.
- **Who would be interested in the results, and why** Researchers in cardiovascular genetics and congenital heart disease may find the prioritized SNP list useful for designing targeted sequencing or functional studies. The molecular dynamics analysis of GATA6 variants could be of interest to computational biologists studying transcription factor structure-function relationships. However, the impact is limited by the lack of experimental follow-up and the absence of novel methodological contributions.
- **Major strengths** The study addresses a clinically relevant question using a multi-step computational approach. The use of multiple prediction tools for cross-validation is appropriate. The molecular dynamics simulations provide a dynamic perspective beyond static predictions. The authors acknowledge the limitations of in silico approaches and call for experimental validation.
- **Major Concerns** See detailed items below.
- **Minor Comments** See detailed items below.
- **Technical failings that need to be addressed before the case is established** R1-M1 (lack of quantitative results), R1-M2 (inconsistent variant prioritization), R1-M3 (overstated causal language), R1-M4 (insufficient methodological detail for reproducibility).
- **Assessment against Nature-style criteria**  
  *Originality*: Low. The application of standard in silico tools to a known gene (GATA6) in a common condition (VSD) does not represent a conceptual advance. Similar analyses have been published for GATA6 and other CHD genes.  
  *Scientific importance*: Moderate. The specific variants identified may be of interest, but the study does not establish a causal role or provide functional evidence. The clinical implications are speculative.  
  *Interdisciplinary readership*: Limited. The work is primarily of interest to a narrow audience of cardiovascular geneticists and computational biologists. The methods are not novel enough to attract a broader readership.  
  *Technical soundness*: Not fully assessable from the supplied material. The described methods are standard, but the absence of quantitative outputs and figures prevents verification. The inconsistency in variant prioritization (four vs. five mutations) is a technical concern.  
  *Readability for nonspecialists*: The manuscript is generally readable, but the methods section is dense and assumes familiarity with multiple bioinformatics tools. The results section lacks clear narrative flow.
- **Recommendation posture** Currently not established from the provided evidence. The manuscript requires major revisions, including the provision of all quantitative data and figures, clarification of the variant selection process, and tempering of causal claims, before the conclusions can be considered supported.

### Major Concerns

- **Concern ID** R1-M1  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Evidence quality  
- **Claim pointer** The authors claim that rs387906818 and rs387906820 have the "highest pathogenic potential for VSD" based on their analyses.  
- **Evidence pointer** Results section, Tables 2-4, Figures 10-12; location not provided for specific data points.  
- **Concern** The central conclusion is based on prediction scores from multiple tools, but none of the actual scores, thresholds, or statistical outputs are reported in the text. The reader cannot evaluate how the "highest pathogenic potential" was determined or whether the differences between variants are meaningful. For example, the MutPred2 scores are mentioned only as "above 0.5" thresholds, and the molecular dynamics results are described qualitatively. Without the underlying data, the claim is not verifiable.  
- **Why it matters** The study's primary contribution is the prioritization of specific variants. If the supporting data are not presented, the conclusion is unsupported and the study loses its scientific value.  
- **Resolution test** Provide all prediction scores for the 17 candidate SNPs in a supplementary table, including SIFT, PolyPene-2, MutPred2, FATHMM, SNP&GO, I-Mutant, and PON-P2 outputs. For molecular dynamics, report quantitative metrics (e.g., RMSD, RMSF, Rg values with standard deviations) and statistical comparisons between wild-type and mutant systems.

- **Concern ID** R1-M2  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Internal consistency  
- **Claim pointer** The abstract and conclusion state that four SNPs were identified (rs387906813, rs387906817, rs387906818, rs387906820), but the molecular dynamics section and Table 6 describe five mutations (R456C, N466H, A467T, T452A, N466D).  
- **Evidence pointer** Abstract, Results section "Molecular dynamics simulation", Table 6.  
- **Concern** The manuscript is internally inconsistent regarding the number of variants taken forward to molecular dynamics. The abstract and conclusion mention four SNPs, but the methods and results describe five mutations. This discrepancy suggests either an error in the variant selection or a failure to clearly document the process. It undermines confidence in the rigor of the analysis.  
- **Why it matters** Reproducibility and clarity are fundamental to scientific reporting. An inconsistency in the core variant list confuses the reader and raises questions about the accuracy of the entire pipeline.  
- **Resolution test** Clarify the exact number of variants analyzed in each step. If five were used, correct the abstract and conclusion. If four were used, explain why N466D was included in Table 6 and the molecular dynamics section.

- **Concern ID** R1-M3  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Claim strength  
- **Claim pointer** The authors state that mutations in GATA6 "may disrupt its normal function, potentially leading to the pathogenesis of VSD" and that the identified variants have "the potential to cause VSD."  
- **Evidence pointer** Discussion section, Conclusion section.  
- **Concern** The language used in the discussion and conclusion implies a causal relationship between the identified SNPs and VSD. However, the study is purely computational and provides no functional or clinical validation. The prediction tools assess likelihood, not causality. The authors do not adequately distinguish between "in silico prediction of pathogenicity" and "demonstrated role in disease."  
- **Why it matters** Overstating the implications of computational findings can mislead readers and potentially influence clinical decision-making. The authors should clearly frame their results as hypothesis-generating.  
- **Resolution test** Revise the discussion and conclusion to use cautious language, such as "predicted to be deleterious" or "candidate variants for further investigation." Explicitly state that experimental validation is required before any clinical relevance can be claimed.

- **Concern ID** R1-M4  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Reproducibility  
- **Claim pointer** The methods describe the use of AlphaFold 3, Yasara Dynamics, GROMACS, and WebGro, but key parameters are missing.  
- **Evidence pointer** Methods section, subsections "Modelling of GATA6 protein and mutation in the conserved area" and "Molecular dynamics and visualization of variant/residue effect predictions".  
- **Concern** The methods lack critical details for reproducibility. For example, the AlphaFold 3 model is not validated against experimental structures or quality metrics. The molecular dynamics simulation parameters (e.g., equilibration protocol, thermostat/barostat settings, simulation time after equilibration) are not fully specified. The use of WebGro as a server-based tool may limit control over simulation conditions.  
- **Why it matters** Without complete methodological details, other researchers cannot replicate the simulations or assess the validity of the results. This is a fundamental requirement for computational studies.  
- **Resolution test** Provide a detailed description of all simulation parameters, including software versions, force field parameters, solvation model, ion concentration, temperature/pressure coupling, and the number of replicates. Include validation metrics for the AlphaFold 3 model (e.g., pLDDT scores, RMSD to experimental structures if available).

### Minor Comments

- **Concern ID** R1-m1  
- **Severity** Minor  
- **Axis** Clarity  
- **Affected element** Figure 1  
- **Evidence pointer** Figure 1, "Flow diagram and research design"  
- **Issue** The flow diagram is referenced but not provided. The text description of the study design is somewhat repetitive and could be streamlined.  
- **Required correction** Ensure the figure is included in the final submission and that the text description aligns with the figure.

- **Concern ID** R1-m2  
- **Severity** Minor  
- **Axis** Data presentation  
- **Affected element** Tables 2-4  
- **Evidence pointer** Tables 2-4  
- **Issue** The tables are not provided. The text describes prediction results but does not summarize them in a way that allows comparison across tools.  
- **Required correction** Include the tables and add a summary paragraph in the results that synthesizes the predictions across all tools, highlighting concordance and discordance.

- **Concern ID** R1-m3  
- **Severity** Minor  
- **Axis** Interpretation  
- **Affected element** Molecular dynamics results  
- **Evidence pointer** Results section, "Molecular dynamics simulation"  
- **Issue** The interpretation of the RMSD and Rg results is somewhat contradictory. The authors state that lower RMSD indicates "structural instability" but also that higher Rg indicates "reduced compactness." These metrics are not directly equivalent, and the interpretation should be more nuanced.  
- **Required correction** Clarify the relationship between RMSD, Rg, and structural stability. Discuss the implications of each metric separately and avoid conflating them.

- **Concern ID** R1-m4  
- **Severity** Minor  
- **Axis** Literature context  
- **Affected element** Discussion section  
- **Evidence pointer** Discussion section  
- **Issue** The discussion cites previous studies on GATA6 mutations in CHD but does not compare the specific variants identified here with those previously reported.  
- **Required correction** Add a comparison of the identified variants (rs387906818, rs387906820) with known GATA6 mutations in CHD, discussing whether these are novel or previously described.

- **Concern ID** R1-m5  
- **Severity** Minor  
- **Axis** Statistical rigor  
- **Affected element** Gene ontology analysis  
- **Evidence pointer** Methods section, "Gene ontology analysis"  
- **Issue** The gene ontology analysis is described as using Fisher's exact test with FDR correction, but the results are not presented with effect sizes or confidence intervals.  
- **Required correction** Report the enrichment scores, fold enrichment values, and confidence intervals for the top terms in each category.

## Risk / unsupported claims
- The claim that rs387906818 and rs387906820 have the "highest pathogenic potential for VSD" is unsupported without the underlying prediction scores and simulation data.
- The claim that GATA6 mutations "may disrupt its normal function, potentially leading to the pathogenesis of VSD" is speculative and not supported by functional evidence.
- The statement that the 16-protein interaction network is "involved in the formation of the atrioventricular septum, the proliferation and differentiation of cardiac muscle cells, and the development of the ventricular septum" is based on gene ontology enrichment but the specific terms and significance levels are not reported.
- The conclusion that "mutations in this protein's functional domain are significant in the process of VSD occurrence" is an overstatement of computational predictions.
- The manuscript does not provide evidence that the prioritized SNPs are absent or rare in control populations, which is a standard requirement for variant prioritization studies.